机构：[1]Department of Urology and Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.四川大学华西医院[2]West China School of Medicine, Sichuan University, Chengdu, Sichuan, China.四川大学华西医院[3]Department of Thyroid and Breast Surgery, The Affiliated Lihuili Hospital, Ningbo University, Ningbo, Zhejiang, China.
The expression and significance of human epidermal growth factor receptor 2 (Her2) in upper tract urothelial carcinoma (UTUC) remains controversial. Thus, we aimed to systemically review the Her2 expression in UTUC patients and its relationship with pathological characters and clinical outcomes with meta-analysis.A systematically computerized search in PubMed, Scopus, Embase and Cochrane was conducted. From a total of 454 related articles, 35 articles were finally reviewed and 16 papers were chosen for further analysis. Pathological characters included tumor stage, grade, lymph node metastasis (LNM) and lymphovascular invasion (LVI). The clinical outcomes included overall survival (OS), recurrence-free survival (RFS), cancer specific survival (CSS), metastatic-free survival (MFS) and progression-free survival (PFS). RevMan software was used for meta-analyses.In total 16 studies from 1994 to 2020 were chosen, 14 studies used immunohistochemistry to assess the expression of Her2 and 5 studies used in situ hybridization, with a positive rate of 0 to 74.0% and 7.2 to 18.1%, respectively. Her2-positive was significantly associated with stage (pooled HR 1.86; 95 % CI 1.43-2.42), grade (pooled HR 2.81; 95 % CI 1.01-7.85) and LNM (pooled HR 1.93; 95 % CI 1.18-3.15). However, there was no statistically relationship between Her2-positive with LVI (pooled HR 1.48; 95 % CI 0.64-3.46) and RFS (pooled HR 1.41; 95 % CI 0.98-1.83).This review indicated that UTUC patients with Her2-positive tended to develop higher stage and grade tumors and LNM. The Her2 expression in UTUC patients deserves further investigation in the future.
基金：
This work was supported by the National Natural Science
Foundation of China (Grant number: 81500522) and Science &
Technology Department of Sichuan Province (Grant number:
2020YFS0090, 2020YFS0046).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类|4 区医学
小类|4 区肿瘤学
最新[2023]版：
大类|4 区医学
小类|4 区肿瘤学
第一作者：
第一作者机构：[1]Department of Urology and Institute of Urology, West China Hospital, Sichuan University, Chengdu, Sichuan, China.[2]West China School of Medicine, Sichuan University, Chengdu, Sichuan, China.
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Ye Jianjun,Liao Xinyang,Qiu Yu,et al.A systematic review and meta-analysis for human epidermal growth factor receptor 2 on upper tract urothelial carcinoma patients[J].Tumori.2023,3008916231186178.doi:10.1177/03008916231186178.
APA：
Ye Jianjun,Liao Xinyang,Qiu Yu,Wei Qiang&Bao Yige.(2023).A systematic review and meta-analysis for human epidermal growth factor receptor 2 on upper tract urothelial carcinoma patients.Tumori,,
MLA：
Ye Jianjun,et al."A systematic review and meta-analysis for human epidermal growth factor receptor 2 on upper tract urothelial carcinoma patients".Tumori .(2023):3008916231186178
